Source: Eur Respir Rev, 27 (150) 180078; 10.1183/16000617.0078-2018
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Colin Holtze, Kevin Flaherty, Michael Kreuter, Fabrizio Luppi, Teng Moua, Carlo Vancheri, Mary B. Scholand. Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. Eur Respir Rev, 27 (150) 180078; 10.1183/16000617.0078-2018

Member's Comments

No comment yet.

Related content which might interest you: Healthcare resource utilization and direct costs of interstitial lung disease management in Germany Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Healthcare utilisation in childhood interstitial lung diseases: Analysis of chILD-EU registry data Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016 Healthcare utilisation, cost and respiratory disease severity Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002 Healthcare costs and resource use in patients with chronic obstructive pulmonary disease (COPD) in Ontario, Canada Source: Virtual Congress 2021 – Primary care organisation and epidemiology Year: 2021 Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Management of chronic lung conditions Year: 2020 Healthcare utilization and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea Source: International Congress 2014 – Respiratory disease within hospital-based populations Year: 2014 Trends in healthcare utilization and costs prior to a chronic obstructive pulmonary disease (COPD) diagnosis Source: Eur Respir J 2006; 28: Suppl. 50, 36s Year: 2006 Benefits from a program for “early interstitial lung diseases” in primary care centers Source: International Congress 2017 – From idiopathic pulmonary fibrosis (IPF) to rare diseases Year: 2017 Diagnostic delay and misdiagnosis in interstitial lung disease(ILD) at primary health care level Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care Year: 2016 Incidence and resource utilisation of pulmonary exacerbations in patients with cystic fibrosis in the UK Source: Annual Congress 2010 - New aspects of cystic fibrosis Year: 2010 Health care system resource utilisation in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 EPIDIA: an App to to assist physicians in the care of patients with interstitial lung diseases Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Profiling of hypersensitivity pneumonitis diagnosed at a UK specialist service for ILD and occupational lung diseases Source: International Congress 2018 – Occupational and environmental lung diseases: asthma and the airways Year: 2018 Integrated care prevents hospitalisations for exacerbations in COPD patients Source: Eur Respir J 2006; 28: 123-130 Year: 2006 Impact of early referral to palliative care in patients with interstitial lung disease Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Interims analysis of the EXCITING-ILD registry (registry for exploring clinical and epidemiological characteristics of interstitial lung diseases) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Palliative and end-of-life care for patients with respiratory disease Source: Eur Respir Mon; 2009: 43:327–353 Year: 2009 Intensive care outcomes in patients with diffuse fibrotic parenchymal lung diseases Source: Annual Congress 2011 - Intensive care outcome Year: 2011 Impact of a specialist respiratory pharmacist in the management of interstitial lung disease Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018